Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies
With widespread global COVID-19 vaccine coverage, a scalable, cost-effective, and standardized tool to ascertain post-vaccine immunity is a dire need. Neither clinical evaluations of vaccine efficacy, nor live virus antibody neutralization assays fulfill these criteria. Commercially available anti-S...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | Journal of Clinical Virology Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667038023000042 |
| _version_ | 1797951556899831808 |
|---|---|
| author | Javeria Aijaz Fatima Kanani Fouzia Naseer |
| author_facet | Javeria Aijaz Fatima Kanani Fouzia Naseer |
| author_sort | Javeria Aijaz |
| collection | DOAJ |
| description | With widespread global COVID-19 vaccine coverage, a scalable, cost-effective, and standardized tool to ascertain post-vaccine immunity is a dire need. Neither clinical evaluations of vaccine efficacy, nor live virus antibody neutralization assays fulfill these criteria. Commercially available anti-S binding immunological assays have the potential to fill this gap, but need to be systematically evaluated for their utility to serve as surrogates for the aforementioned, widely accepted tools of determining vaccine efficacy. In this study, we evaluated an anti-S binding immunological assay (Roche Elecsys Anti-SARS-CoV-2 S) by utilizing two hundred and fifty-five archived serum specimens, either pre-pandemic, or those exposed to natural infections or vaccines with their neutralizing titers pre-determined through a live virus, pseudotyped antibody neutralization assay. Roche Elecsys Anti-SARS-CoV-2 S demonstrated good sensitivity (98%) and specificity (99%), just as has been reported in some other previously conducted studies using this assay. Only a mild correlation, however, with the live virus pseudotyped lentivirus antibody neutralization assay (Spearman's r = 0.26) was observed. We conclude that, as such, Elecsys Anti-SARS-CoV-2 S has a high sensitivity and specificity for detecting anti-SARS-CoV-2 S proteins, though the assay does not always correlate well with live virus assays for quantitative outcomes. |
| first_indexed | 2024-04-10T22:32:25Z |
| format | Article |
| id | doaj.art-f68d85fe983f4136908c75d6a760b77a |
| institution | Directory Open Access Journal |
| issn | 2667-0380 |
| language | English |
| last_indexed | 2024-04-10T22:32:25Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical Virology Plus |
| spelling | doaj.art-f68d85fe983f4136908c75d6a760b77a2023-01-17T04:07:35ZengElsevierJournal of Clinical Virology Plus2667-03802023-02-0131100137Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodiesJaveria Aijaz0Fatima Kanani1Fouzia Naseer2Molecular Biology Section, Pathology Department, Indus Hospital and Health Network, Plot C-76, Sector 31/5, Opposite، Crossing، Darussalam Society Sector 39 Korangi, Karachi, Sindh, Pakistan; Corresponding author.Chemical Pathology Section, Pathology Department, Indus Hospital & Health Network, Karachi, PakistanMolecular Biology Section, Pathology Department, Indus Hospital and Health Network, Plot C-76, Sector 31/5, Opposite، Crossing، Darussalam Society Sector 39 Korangi, Karachi, Sindh, PakistanWith widespread global COVID-19 vaccine coverage, a scalable, cost-effective, and standardized tool to ascertain post-vaccine immunity is a dire need. Neither clinical evaluations of vaccine efficacy, nor live virus antibody neutralization assays fulfill these criteria. Commercially available anti-S binding immunological assays have the potential to fill this gap, but need to be systematically evaluated for their utility to serve as surrogates for the aforementioned, widely accepted tools of determining vaccine efficacy. In this study, we evaluated an anti-S binding immunological assay (Roche Elecsys Anti-SARS-CoV-2 S) by utilizing two hundred and fifty-five archived serum specimens, either pre-pandemic, or those exposed to natural infections or vaccines with their neutralizing titers pre-determined through a live virus, pseudotyped antibody neutralization assay. Roche Elecsys Anti-SARS-CoV-2 S demonstrated good sensitivity (98%) and specificity (99%), just as has been reported in some other previously conducted studies using this assay. Only a mild correlation, however, with the live virus pseudotyped lentivirus antibody neutralization assay (Spearman's r = 0.26) was observed. We conclude that, as such, Elecsys Anti-SARS-CoV-2 S has a high sensitivity and specificity for detecting anti-SARS-CoV-2 S proteins, though the assay does not always correlate well with live virus assays for quantitative outcomes.http://www.sciencedirect.com/science/article/pii/S2667038023000042RocheElecsysCOVID-19AntibodiesNeutralizing |
| spellingShingle | Javeria Aijaz Fatima Kanani Fouzia Naseer Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies Journal of Clinical Virology Plus Roche Elecsys COVID-19 Antibodies Neutralizing |
| title | Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies |
| title_full | Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies |
| title_fullStr | Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies |
| title_full_unstemmed | Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies |
| title_short | Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies |
| title_sort | utility of roche elecsys anti sars cov 2 s in ascertaining post vaccine neutralizing antibodies |
| topic | Roche Elecsys COVID-19 Antibodies Neutralizing |
| url | http://www.sciencedirect.com/science/article/pii/S2667038023000042 |
| work_keys_str_mv | AT javeriaaijaz utilityofrocheelecsysantisarscov2sinascertainingpostvaccineneutralizingantibodies AT fatimakanani utilityofrocheelecsysantisarscov2sinascertainingpostvaccineneutralizingantibodies AT fouzianaseer utilityofrocheelecsysantisarscov2sinascertainingpostvaccineneutralizingantibodies |